Enterprise Value
1.559B
Cash
331.1M
Avg Qtr Burn
-49.12M
Short % of Float
13.63%
Insider Ownership
3.76%
Institutional Own.
96.69%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RP-L102 Details Rare diseases, Blood disorder | BLA Submission | |
RP-L201 Details Immunodeficiency | BLA Submission | |
RP-L301 Details Pyruvate Kinase Deficiency | Phase 2 Initiation | |
RP-A501 Details Immunodeficiency | Phase 2 Initiation | |
RP-L401 Details Infantile Malignant Osteopetrosis (IMO) | Phase 1 Update | |
RP-A601 Details Heart disease | Phase 1 Initiation |